^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Uterine Cancer

    Related cancers:
    1d
    Cancer-associated fibroblast activation protein in Appalachian women with uterine cervix cancer. (PubMed, Front Oncol)
    Cancer-associated fibroblast FAP immunoreactivity in this series indicates that [212Pb]Pb-PSV-359 radiopharmaceutical therapy might have usefulness in women with persistent, recurrent or metastatic uterine cervix cancer. A phase I clinical trial inclusive of metastatic uterine cervix cancer patients is underway (NCT06710756).
    Journal
    |
    FAP (Fibroblast activation protein, alpha)
    1d
    Changes in Uterine Artery Resistance Index Following Cervical Conization (clinicaltrials.gov)
    P=N/A, N=50, Completed, Adana City Training and Research Hospital
    New trial
    2d
    Clinicopathological, Molecular and DNA Methylation Analysis of Ossifying Fibromyxoid Tumors Delineates the ZC3H7B::BCOR Subset as a Distinct Entity. (PubMed, Mod Pathol)
    Additionally, DNA methylation profiling distinguished ZC3H7B::BCOR-rearranged cases from other fusion-positive OFMT, whereas the former clustered closely with a subset of high-grade endometrial stromal sarcomas. This study supports the recognition of ZC3H7B::BCOR-positive tumors as a distinct clinicopathological entity, contributing to the refined molecular taxonomy of this neoplasm.
    Journal
    |
    CREBBP (CREB binding protein) • BCOR (BCL6 Corepressor) • EP300 (E1A binding protein p300) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • BMI1 (BMI1 proto-oncogene, polycomb ring finger) • EP400 (E1A Binding Protein P400) • PRKAG1 (Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 1) • AFF3 (AF4/FMR2 Family Member 3) • BCORL1 (BCL6 Corepressor Like 1)
    3d
    High-grade Endometrial Stromal Sarcoma With a Novel ING3::BCOR Fusion. (PubMed, Int J Gynecol Pathol)
    HGESS with BCOR fusion should be considered in tumors with a combination of spindle cell growth, myxoid background, foci of coagulative necrosis, diffuse cyclin D1 positivity, and a negative hormone receptor status. Accurate diagnosis requires an integrated approach that combines histopathologic evaluation, IHC, and molecular testing.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • CCND1 (Cyclin D1) • BCOR (BCL6 Corepressor) • CD34 (CD34 molecule) • ALK1 (Activin A Receptor Like Type 1) • MME (Membrane Metalloendopeptidase)
    4d
    mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (clinicaltrials.gov)
    P1, N=159, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)
    6d
    Subtype-Specific Prognosis, Recurrence Patterns, and Molecular Features in 148 Chinese Uterine Sarcomas: A Real-World Study. (PubMed, Cancers (Basel))
    Histological subtype, stage, and coagulative necrosis were critical prognostic factors in uterine sarcoma. The findings suggest that vigilant pulmonary surveillance and further investigation into tailored therapeutic strategies may be warranted-including endocrine therapy for hormone-receptor-positive tumors, immunotherapy for high-grade ESS, and PARP inhibitors for uLMS. However, these hypotheses require thorough preclinical and clinical validation. Additionally, caution should be exercised to avoid overtreatment of chemotherapy in early-stage uLMS.
    Journal • Real-world evidence • PARP Biomarker • IO biomarker
    |
    CSF3R (Colony Stimulating Factor 3 Receptor) • CSF1R (Colony stimulating factor 1 receptor)
    |
    HR positive
    6d
    Generation of a stable mouse endometrial tumor-derived cell line using conditional reprogramming. (PubMed, Biol Res)
    The isolated mouse cell line provides a powerful platform for basic and translational EC studies, matching well with the corresponding in vivo models. The fidelity of the cell line to human-relevant genetic alterations and tumor biology makes it a valuable tool for investigating EC pathogenesis and evaluating novel therapeutic approaches.
    Preclinical • Journal
    |
    PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    6d
    Nudging Preventive Screening Via Message Framing and Bundling (clinicaltrials.gov)
    P=N/A, N=235000, Not yet recruiting, University of Chile
    New trial
    7d
    GOLD: Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic Oncology (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    New trial
    7d
    An integrative mutational and network analysis of pancreatic cancer reveals key genes, and signalling pathways. (PubMed, Funct Integr Genomics)
    Invitae and Fulgent offer the broadest gene coverage (20/21), with 16 genes universally covered by all four providers, while GeneD and Prevention Genetics lag at 17 genes each, with critical gaps in rare cancer predisposition genes like TSC1, TSC2, and NF1. Overall, these findings refine the molecular landscape of PC and highlight key genes and pathways with potential clinical relevance.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1) • RNF43 (Ring Finger Protein 43) • SMAD4 (SMAD family member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MUC16 (Mucin 16, Cell Surface Associated) • TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1) • RBBP8 (RB Binding Protein 8, Endonuclease) • TGFB1 (Transforming Growth Factor Beta 1) • ACVR1B (Activin A Receptor Type 1B)
    |
    TP53 mutation • KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12R • KRAS G12
    8d
    Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Nov 2026 | Trial primary completion date: Jun 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Triapine (3-AP)
    8d
    GPNMB immunohistochemistry distinguishes diagnostically challenging cases of lymphangioleiomyomatosis from other mesenchymal neoplasms presenting with cystic lung metastases. (PubMed, Hum Pathol)
    Our data show that GPNMB is highly expressed by LAM in the lung, with immunohistochemistry performance similar to cathepsin K but superior to traditional melanocytic markers. GPNMB may be useful to confirm diagnostically challenging cases of LAM and to exclude most non-PEComatous mimics presenting with cystic lung metastases, but metastatic dermatofibromas can be a diagnostic pitfall.
    Journal
    |
    GPNMB (Glycoprotein Nmb) • MLANA (Melan-A) • CTSK (Cathepsin K) • MITF (Melanocyte Inducing Transcription Factor)